BioWorld Science

May 18, 2017

View Archived Issues

Otsuka Pharmaceutical recaps highlights of first quarter 2017

Read More

LV.CD11b.IDS for the treatment of neurocognitive impairments in an MPS II mouse model

Read More

FDA places CTP-543 phase IIa study on hold

Read More

Shire initiates phase I study of SHP-639 in intraocular hypertension and primary open-angle glaucoma

Read More

Promising clinical results seen with AAV2-AADC for AADC deficiency

Read More

rAAV9-CBA-hNAGLUop optimized gene delivery for treating MPS IIIB

Read More

FDA approves Kalydeco to treat cystic fibrosis in patients with certain residual function mutations

Read More

Omeros provides update on phase II study of OMS-721

Read More

Bristol-Myers Squibb patents casein kinase II inhibitors

Read More

Vifor presents ferroportin inhibitors

Read More

Aurinia initiates phase III study of voclosporin for lupus nephritis

Read More

Quanterix launches Simoa Neurology 4-Plex A assay to study traumatic brain injury severity

Read More

Heptares Therapeutics identifies calcitonin gene-related peptides receptor antagonists

Read More

FDA grants breakthrough therapy designation to GMI-1271 for relapsed or refractory AML

Read More

Merck & Co. discovers coagulation factor XIa and kallikrein inhibitors

Read More

Sun Pharma Advanced Research discloses estrogen receptor antagonists

Read More

Aduro Biotech expands clinical collaboration with Merck & Co.

Read More

Nanobiotix reports clinical data on potential role of NBTXR-3 in immuno-oncology

Read More

Teva nominates preclinical candidate CGRP antagonist for advancement to treat migraine

Read More

NC16A IgG4 may be a serum diagnostic marker of eosinophilic esophagitis

Read More

Specialised Therapeutics and PharmaMar enter lurbinectedin licensing agreement

Read More

miR-155 found as a predictor of methotrexate nonresponse in rheumatoid arthritis patients

Read More

Evaluation of novel anti-MUC1 (CAR)-modified T cells for the treatment of breast cancer

Read More